(3,5-二甲氧基苄基)甲胺; 1-(3,5-二甲氧基苯基)-N-甲基甲胺 | 77775-71-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (3,5-二甲氧基苄基)甲胺; 1-(3,5-二甲氧基苯基)-N-甲基甲胺
• 中文别名: (3,5-二甲氧基苄基)甲胺1-(3,5-二甲氧基苯基)-N-甲基甲胺1-(3,5-Dimethoxyphenyl)-N-methylmethanamine；(3,5-二甲氧基苄基)甲胺；(3,5-二甲氧基苄基)甲胺;1-(3,5-二甲氧基苯基)-N-甲基甲胺；1-(3,5-二甲氧基苯基)-N-甲基甲胺
• 英文名称: N-methyl-3,5-dimethoxybenzylamine
• 英文别名: 1-(3,5-dimethoxyphenyl)-N-methylmethanamine；(3,5-dimethoxy-benzyl)-methyl-amine；(3,5-Dimethoxybenzyl)methylamine
• CAS: 77775-71-4
• 化学式: C₁₀H₁₅NO₂
• mdl: MFCD05864733
• 分子量: 181.235
• InChiKey: AZLYFFWKOFXIRJ-UHFFFAOYSA-N

物化性质

• 沸点：
  272.7±25.0 °C(Predicted)
• 密度：
  1.012±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (3,5-二甲氧基苄基)甲胺; 1-(3,5-二甲氧基苯基)-N-甲基甲胺 在 氨 、 lithium 、 叔丁醇 作用下， 反应 2.0h， 生成 (3,5-Dimethoxy-cyclohexa-2,5-dienylmethyl)-methyl-amine
  参考文献：
  名称：

  Synthesis and activity of 5-(aminomethyl)-1,3-cyclohexanediones: enolic analogs of .gamma.-aminobutyric acid

  摘要：

  Eight 1,3-cyclohexanediones with an aminoalkyl side chain in the 5-position were synthesized as rigid enolic analogues of GABA (gamma-aminobutyric acid). Biochemical investigations about their abilities to displace [3H]GABA and [3H]baclofen [beta-(p-chlorophenyl)-gamma-aminobutyric acid] in binding studies or to inhibit the high-affinity sodium-dependent GABA uptake showed that these compounds were generally devoid of affinity for the two GABA receptors and for the GABA carrier. Only compound 1 exhibited a weak affinity in the GABA-A binding experiments (IC50 = 6.5 X 10(-5) M). Graphic computer modeling was applied in an attempt to explain this activity in comparison to some reference GABA agonists. Electrophysiological studies on dorsal root ganglia (DRG) also excluded agonistic or antagonistic properties on GABA-A or GABA-B receptor models but pointed out an atypical prolongation of Ca2+-dependent action potential for compound 1.

  DOI：

  10.1021/jm00148a012
• 作为产物：
  描述：

  3,5-二甲氧基苯甲醛 、 甲胺 在 sodium tetrahydroborate 作用下， 生成 (3,5-二甲氧基苄基)甲胺; 1-(3,5-二甲氧基苯基)-N-甲基甲胺
  参考文献：
  名称：

  Photochemical synthesis of 1,2,3,4-tetrahydroisoquinolin-3-ones and oxindoles from N-chloroacetyl derivatives of benzylamines and anilines. Role of intramolecular exciplex formation and cis conformation of amide bonds.

  摘要：

  虽然苄胺（2、8）和苯胺（21、25、29）的 N-氯乙酰基衍生物在高压汞灯照射下会迅速消失，但并没有发生六元和五元内酰胺的光环化反应。对不同烷基链长度的 N-氯乙酰基-(3, 4-二甲氧基苯基)-烷基胺的荧光淬灭和消失量子产率的测量表明，烷基链越短，形成复合物的效率越高。因此，光环化失败似乎是由于苄胺和苯胺衍生物中酰胺键的反式构象造成的。因此，N-烷基-N-氯乙酰基苄胺（11、13、15、17、19）在辐照下很容易生成相应的 1、2、3、4-四氢异喹啉-3-酮（12、14、16、18、20）。通过 N-烷基-N-氯乙酰苯胺（35、37、39、42、45）的光环化反应，也同样合成了氧化吲哚（36、38、40、41、43、46）。

  DOI：

  10.1248/cpb.29.128

文献信息

• WDR5 INHIBITORS AND MODULATORS
  申请人：Vanderbilt University

  公开号：US20200102288A1

  公开（公告）日：2020-04-02

  Described are imino-azacycle-benzamide compounds compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.

  描述了抑制WDR5和相关蛋白质-蛋白质相互作用的亚氨基-氮杂环-苯甲酰胺化合物，包括这些化合物的药物组合物，以及使用这些化合物和组合物治疗受试者疾病和状况的方法。
• The Use of Potassium/Sodium Nitrite as a Nitrosating Agent in the Electrooxidative <i>N</i> ‐Nitrosation of Secondary Amines
  作者：Ying Wang、Shiqi You、Mengyao Ruan、Feiyi Wang、Chao Ma、Cuifen Lu、Guichun Yang、Zuxing Chen、Meng Gao

  DOI：10.1002/ejoc.202100363

  日期：2021.6.14

  An efficient and environmentally electrooxidative N-nitrosation of secondary amines using potassium/sodium nitrite as nitrosating agents has been developed. This strategy break through the innate combination of sodium nitrite and a strong acid. The reaction is compatible with the late-stage modification of pharmaceutical compounds and could be conducted in gram scale with high reaction efficiency.

  已经开发了一种使用亚硝酸钾/亚硝酸钠作为亚硝化剂的仲胺的有效和环境电氧化N-亚硝化。这种策略突破了亚硝酸钠和强酸的先天组合。该反应与药物化合物的后期修饰相容，可以以克级规模进行，反应效率高。
• [EN] NEW 6-MEMBERED HETEROAROMATIC SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE CYANOINDOLINE À SUBSTITUTION HÉTÉROAROMATIQUE À 6 CHAÎNONS UTILISÉS COMME INHIBITEURS DE NIK
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017125534A1

  公开（公告）日：2017-07-27

  The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及公式（I）的药物制剂，用于治疗和/或预防哺乳动物，特别是用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病的NF-KB诱导激酶（NIK - 也称为MAP3K14）抑制剂。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、包括肥胖和糖尿病在内的代谢性疾病以及自身免疫性疾病的用途。
• [EN] NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE CYANOINDOLINE UTILISÉS COMME INHIBITEURS DE NIK
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017125530A1

  公开（公告）日：2017-07-27

  The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF- KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及一种公式（I）的药物制剂，用于治疗和/或预防哺乳动物中的疾病，特别是用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病的NF-KB诱导激酶（NIK，也称为MAP3K14）的抑制剂。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、包括肥胖和糖尿病在内的代谢性疾病以及自身免疫性疾病的用途。
• WDR5-MLL1 INHIBITORS AND MODULATORS
  申请人：Vanderbilt University

  公开号：US20200055824A1

  公开（公告）日：2020-02-20

  Benzamides and picolinamides that are meta-substituted with imino-, guanidino-, or heterocycle-containing groups disrupt the WDR5-MLL1 protein-protein interaction, and have use in pharmaceutical compositions and in treating proliferative disorders and conditions in a subject, such as cancer.

  苯甲酰胺和吡啶甲酰胺，它们在间位被亚胺基、胍基或含杂环基团取代，会破坏WDR5-MLL1蛋白质间相互作用，并可用于制药组合物中，用于治疗受试者中的增殖性疾病和状况，如癌症。